242 related articles for article (PubMed ID: 26791134)
1. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
[No Abstract] [Full Text] [Related]
2. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
Kitagawa K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
[TBL] [Abstract][Full Text] [Related]
3. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
4. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
Uchida C; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
[TBL] [Abstract][Full Text] [Related]
5. Role of E3 ubiquitin ligases in gastric cancer.
Hou YC; Deng JY
World J Gastroenterol; 2015 Jan; 21(3):786-93. PubMed ID: 25624711
[TBL] [Abstract][Full Text] [Related]
6. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
[TBL] [Abstract][Full Text] [Related]
7. [The role of different E3 ubiquitin ligases in regulation of the P53 tumor suppressor protein].
Daks AA; Melino D; Barlev NA
Tsitologiia; 2013; 55(10):673-87. PubMed ID: 25509121
[TBL] [Abstract][Full Text] [Related]
8. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
9. NEDD4: a promising target for cancer therapy.
Ye X; Wang L; Shang B; Wang Z; Wei W
Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
[TBL] [Abstract][Full Text] [Related]
10. The application of ubiquitin ligases in the PROTAC drug design.
Chen Y; Jin J
Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
[TBL] [Abstract][Full Text] [Related]
11. E3 ubiquitin ligases in cancer and implications for therapies.
Wang D; Ma L; Wang B; Liu J; Wei W
Cancer Metastasis Rev; 2017 Dec; 36(4):683-702. PubMed ID: 29043469
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer.
Inoue Y; Itoh Y; Sato K; Kawasaki F; Sumita C; Tanaka T; Morishita D; Hayashi H
Curr Cancer Drug Targets; 2016; 16(2):110-8. PubMed ID: 26560121
[TBL] [Abstract][Full Text] [Related]
13. Targeted protein degradation: expanding the toolbox.
Schapira M; Calabrese MF; Bullock AN; Crews CM
Nat Rev Drug Discov; 2019 Dec; 18(12):949-963. PubMed ID: 31666732
[TBL] [Abstract][Full Text] [Related]
14. Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer.
Liu L; Wong CC; Gong B; Yu J
Oncogene; 2018 Jan; 37(2):148-159. PubMed ID: 28925398
[TBL] [Abstract][Full Text] [Related]
15. Drugging the undruggable: targeting challenging E3 ligases for personalized medicine.
Galdeano C
Future Med Chem; 2017 Mar; 9(4):347-350. PubMed ID: 28263082
[No Abstract] [Full Text] [Related]
16. Biological influence of Hakai in cancer: a 10-year review.
Aparicio LA; Valladares M; Blanco M; Alonso G; Figueroa A
Cancer Metastasis Rev; 2012 Jun; 31(1-2):375-86. PubMed ID: 22349934
[TBL] [Abstract][Full Text] [Related]
17. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
Cruzalegui F
Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
[No Abstract] [Full Text] [Related]
18. Ubiquitin Drug Discovery and Diagnostics Conference - targeting E3 ligases.
Johnston JA
IDrugs; 2010 Oct; 13(10):695-7. PubMed ID: 20878590
[TBL] [Abstract][Full Text] [Related]
19. Parkin: A targetable linchpin in human malignancies.
Perwez A; Wahabi K; Rizvi MA
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188533. PubMed ID: 33785381
[TBL] [Abstract][Full Text] [Related]
20. Targeting neddylation in cancer therapy.
Duncan K; Schäfer G; Vava A; Parker MI; Zerbini LF
Future Oncol; 2012 Nov; 8(11):1461-70. PubMed ID: 23148618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
